Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zeo ScientifiX ( (ZEOX) ) has provided an update.
On April 7, 2026, ZEO ScientifiX announced it had been selected as a Qualified Team advancing to the Semi-Finals of the $101 million XPRIZE Healthspan competition, which seeks therapies that roll back muscle, cognitive, and immune aging in older adults. The company is now preparing its Finals Application, aiming to move its regenerative biologics platform into controlled clinical evaluation to generate human safety and functional data aligned with the competition’s objectives.
To support this effort, ZEO has assembled a multidisciplinary team of leading experts in gene therapy, telomere biology, exosome science, regenerative medicine, biostatistics, and advanced biologics manufacturing. The semi-final berth, coupled with its recent role as regenerative medicine educational partner to the American Academy of Anti-Aging Medicine, underscores ZEO’s bid to strengthen its position in the longevity and regenerative medicine space and could have strategic implications for its clinical development trajectory.
More about Zeo ScientifiX
ZEO ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, and manufacturing regenerative biologics, including extracellular vesicle therapeutics and advanced delivery systems. Operating from Nova Southeastern University’s Center for Collaborative Research in Florida, the company targets aging and inflammation by translating emerging science into scalable clinical solutions.
Average Trading Volume: 6,241
Technical Sentiment Signal: Buy
Current Market Cap: $15.63M
For an in-depth examination of ZEOX stock, go to TipRanks’ Overview page.